News on NGS technologies, RNA-seq, clinical sequencing, & sample prep in genetics, genomics, and molecular diagnostics.
The groups will use Helomics' artificial intelligence-based platform to develop tools to provide predictive therapeutic recommendations for ovarian and thyroid cancers.
The firm is using automated laboratory testing, artificial intelligence, and single-cell omics for a "precision" approach to cancer drug discovery.
A Personalized Medicine Coalition-funded study has found that NGS-based testing is moderately cost effective but that access to targeted treatments remains a hurdle.
Regulators in the country granted additional approval of the test as a companion diagnostic for Rozlytrek, marketed in Japan by Roche's Chugai Pharmaceutical.
A New York Genome Consortium-led team plans retrospective and prospective analyses on very rare cancers in the hopes of improving treatment options available for patients.
